Ishichi Y - Search Results

1

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.

Yukawa T, Nakada Y, Sakauchi N, Kamei T, Yamada M, Ohba Y, Fujimori I, Ueno H, Takiguchi M, Kuno M, Kamo I, Nakagawa H, Fujioka Y, Igari T, Ishichi Y, Tsukamoto T. Yukawa T, et al. Among authors: ishichi y. Bioorg Med Chem. 2016 Aug 15;24(16):3716-26. doi: 10.1016/j.bmc.2016.06.014. Epub 2016 Jun 8. Bioorg Med Chem. 2016. PMID: 27325446

2

Novel triple reuptake inhibitors with low risk of CAD associated liabilities: design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds.

Ishichi Y, Kimura E, Honda E, Yoshikawa M, Nakahata T, Terao Y, Suzuki A, Kawai T, Arakawa Y, Ohta H, Kanzaki N, Nakagawa H, Terauchi J. Ishichi Y, et al. Bioorg Med Chem. 2013 Aug 1;21(15):4600-13. doi: 10.1016/j.bmc.2013.05.025. Epub 2013 May 24. Bioorg Med Chem. 2013. PMID: 23769168

3

Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.

Honda E, Ishichi Y, Kimura E, Yoshikawa M, Kanzaki N, Nakagawa H, Terao Y, Suzuki A, Kawai T, Arakawa Y, Ohta H, Terauchi J. Honda E, et al. Among authors: ishichi y. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3898-902. doi: 10.1016/j.bmcl.2014.06.046. Epub 2014 Jun 24. Bioorg Med Chem Lett. 2014. PMID: 25017029

4

Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.

Fujimori I, Yukawa T, Kamei T, Nakada Y, Sakauchi N, Yamada M, Ohba Y, Takiguchi M, Kuno M, Kamo I, Nakagawa H, Hamada T, Igari T, Okuda T, Yamamoto S, Tsukamoto T, Ishichi Y, Ueno H. Fujimori I, et al. Among authors: ishichi y. Bioorg Med Chem. 2015 Aug 1;23(15):5000-5014. doi: 10.1016/j.bmc.2015.05.017. Epub 2015 May 15. Bioorg Med Chem. 2015. PMID: 26051602

5

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors-Part 2.

Yukawa T, Fujimori I, Kamei T, Nakada Y, Sakauchi N, Yamada M, Ohba Y, Ueno H, Takiguchi M, Kuno M, Kamo I, Nakagawa H, Fujioka Y, Igari T, Ishichi Y, Tsukamoto T. Yukawa T, et al. Among authors: ishichi y. Bioorg Med Chem. 2016 Jul 15;24(14):3207-17. doi: 10.1016/j.bmc.2016.05.038. Epub 2016 May 21. Bioorg Med Chem. 2016. PMID: 27255177

6

Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF₁ receptor antagonist.

Mochizuki M, Kojima T, Kobayashi K, Kotani E, Ishichi Y, Kanzaki N, Nakagawa H, Okuda T, Kosugi Y, Yano T, Sako Y, Tanaka M, Aso K. Mochizuki M, et al. Among authors: ishichi y. Bioorg Med Chem. 2017 Mar 1;25(5):1556-1570. doi: 10.1016/j.bmc.2016.11.011. Epub 2016 Nov 8. Bioorg Med Chem. 2017. PMID: 28174066

7

Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine.

Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y, Ishimaru T, Saga O, Shirafuji H, Tanaka T, Kamo I, Doi T, et al. Natsugari H, et al. Among authors: ishichi y. J Med Chem. 1995 Aug 4;38(16):3106-20. doi: 10.1021/jm00016a014. J Med Chem. 1995. PMID: 7543579

8

Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.

Ikeura Y, Ishichi Y, Tanaka T, Fujishima A, Murabayashi M, Kawada M, Ishimaru T, Kamo I, Doi T, Natsugari H. Ikeura Y, et al. Among authors: ishichi y. J Med Chem. 1998 Oct 22;41(22):4232-9. doi: 10.1021/jm980042m. J Med Chem. 1998. PMID: 9784098

9

Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.

Natsugari H, Ikeura Y, Kamo I, Ishimaru T, Ishichi Y, Fujishima A, Tanaka T, Kasahara F, Kawada M, Doi T. Natsugari H, et al. Among authors: ishichi y. J Med Chem. 1999 Sep 23;42(19):3982-93. doi: 10.1021/jm990220r. J Med Chem. 1999. PMID: 10508446

10

Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds.

Ishichi Y, Sasaki M, Setoh M, Tsukamoto T, Miwatashi S, Nagabukuro H, Okanishi S, Imai S, Saikawa R, Doi T, Ishihara Y. Ishichi Y, et al. Bioorg Med Chem. 2005 Mar 15;13(6):1901-11. doi: 10.1016/j.bmc.2005.01.022. Bioorg Med Chem. 2005. PMID: 15727846

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters